A 67-year-old man underwent nephrectomy for renal cell carcinoma in July 2014. He began pazopanib treatment for pulmonary metastases from renal cell carcinoma in September 2015．
After five months’ administration of pazopanib, he developed cough and was admitted to our hospital because a chest computed tomography (CT) scan showed ground-glass opacity in both lungs. After admission, levofloxacin was administered intravenously and pazopanib discontinued. Bronchoalveolar lavage was performed two days after cessation of the pazopanib administration, and analysis of bronchoalveolar lavage fluid showed an increased percentage of eosinophils. Seven days after admission, chest CT scan showed that the airspace opacification had improved. However, nine months later a urologist prescribed pazopanib a second time because of further growth in pulmonary metastases from the renal cell carcinoma. Three months later, the man was admitted to our hospital because of bilateral abnormal lung shadowing. After cessation of pazopanib, his symptoms and the ground-glass opacities in his bilateral lung fields improved spontaneously. Consequently, he was diagnosed with drug-induced lung injury caused by pazopanib. The possibility that drug-induced lung injury can be caused by pazopanib must be borne in mind.